CHCWM – Cancer & Hematology Centers of West Michigan

SY-5609-101 (Syros)

SY-5609-101 (Syros)

Description:  A Phase 1 Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients with Select Advanced Solid Tumors

Mechanism of Action:  CDK7 inhibitor

Target Patient Population:   Metastatic breast cancer, ovarian, lung, colorectal or any malignancy with mutation of RB1, CDKN1A/CDKN2A, amplification of CCNE1, CCND1, CCND2, CDK4 or CDK6); in combination with gemcitabine or gemcitabine/nab-paclitaxel in pancreatic cancer

Study Design:  Drug is given orally daily.